Michael Gabrilovich, MD
Pulmonary Disease · Hamilton, OHNPI 1346322005
Payments from drug & device makers
Across 420 payments — averaging $56.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$8K
- Noah Medical Corporation$3K
- Pulmonx Corporation$3K
- AstraZeneca$2K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$945
- plus $5K from 26 others
What the payments were for
- Consulting fees$1,2988%
- Travel & lodging$4,55728%
- Food & beverage$10,25863%
- Education$2722%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 17 | $7,679 |
| Noah Medical Corporation | 16 | $3,487 |
| Pulmonx Corporation | 14 | $2,859 |
| AstraZeneca | 47 | $1,911 |
| GSK | 88 | $1,587 |
| Regeneron Healthcare Solutions, Inc. | 36 | $945 |
| Sanofi | 40 | $814 |
| Grifols USA, LLC | 31 | $720 |
| Olympus Corporation Of The Americas | 9 | $698 |
| Mylan Specialty L.p. | 21 | $468 |
| Cipla USA Inc. | 1 | $300 |
| Amgen | 9 | $277 |
| Viatris Specialty LLC | 9 | $276 |
| Inogen, Inc. | 17 | $257 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $239 |
| Sunovion Pharmaceuticals Inc. | 7 | $179 |
| United Therapeutics Corporation | 7 | $166 |
| Insmed, Inc. | 6 | $160 |
| Genentech USA, Inc. | 7 | $159 |
| Actelion Pharmaceuticals US, Inc. | 6 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Electromed, Inc. | 7 | $92 |
| Pfizer | 1 | $57 |
| Merck | 3 | $54 |
| Gilead | 2 | $49 |
| Vifor Pharma, Inc. | 1 | $30 |
| Baxter Healthcare | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Verona Pharma, Inc. | 1 | $22 |
| Covis Pharma GmbH | 1 | $21 |
| Philips North America LLC | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALAXY$3,184
- CHARTIS CATHETER$2,585
- ZEPHYR ENDOBRONCHIAL VALVE$2,585
- ZEPHYR DELIVERY CATHETER$2,585
- PULMONX CHARTIS TABLET CONSOLE$2,585
- TEZSPIRE$903
- Olympus Bronchoscopes$570
- Olympus Capital Accessories$570
- Olympus Respiratory Accessories$570
- BREZTRI$538
- AIRSUPRA$423
- FASENRA$413
- DUPIXENT$363
- Yupelri$231
- ONGLYZA$176
- Prolastin-C Liquid$126
- AREXVY$122
- NUCALA$121
- LONHALA MAGNAIR$119
How this compares
$23,791 in reported general payments places this provider in the 80th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 24 | $304,954 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 216 | $157,089 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $134,731 |
| Dupixent PenDupilumab | 32 | $129,250 |
| Spiriva RespimatTiotropium Bromide | 70 | $60,890 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $28,243 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $21,222 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $19,950 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $17,842 |
| Roflumilast | 34 | $5,317 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,132 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 118 | $3,832 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $1,545 |
| Montelukast Sodium | 82 | $383 |
| Fluticasone Propionate | 31 | $329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $7,679 | $394,087132 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,911 | $178,311264 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,587 | $176,655216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Hamilton
- David DinuoscioHamilton$91K
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.